Risk of death, hospitalization and intensive care unit admission by SARS-CoV-2 variants in Peru: a retrospective study

被引:7
作者
Fano-Sizgorich, Diego [1 ,2 ]
Vasquez-Velasquez, Cinthya [1 ,3 ]
Orellana, Laura R. [4 ]
Ponce-Torres, Christian [2 ]
Gamboa-Serpa, Henry [5 ]
Alvarez-Huambachano, Keyla [3 ]
Gonzales, Gustavo F. [1 ]
机构
[1] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Biol & Fisiol, Lab Endocrinol & Reprod, Lima, Peru
[2] Univ Peruana Cayetano Heredia, Latin Amer Ctr Excellence Climate Change & Hlth, Lima, Peru
[3] Direcc Reg Salud Callao, Direcc Lab Salud Publ, Callao, Peru
[4] Univ Peruana Cayetano Heredia, Fac Salud Publ & Adm, Emerging Dis & Climate Change Res Unit, EMERGE, Lima, Peru
[5] Direcc Reg Salud Callao, Callao, Peru
基金
美国国家卫生研究院;
关键词
SARS-CoV-2; variants; Clinical outcomes; COVID-19; Peru;
D O I
10.1016/j.ijid.2022.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Peru has had the highest death toll from the pandemic worldwide; however, it is not clear what the effects of the different variants on these outcomes are. The study aimed to evaluate the risk of death, hospitalization, and intensive care unit (ICU) admission rates of COVID-19 according to the SARSCoV-2 variants detected in Peru from March 2020-February 2022.Methods: Retrospective study using open-access databases were published by the Peruvian Ministry of Health. Databases of genomic sequencing, death, COVID-19 cases, hospitalization and ICU, and vaccination were used. Crude and adjusted Cox proportional hazards regressions with clustered variances were modeled to calculate the hazard ratio (HR) of outcomes by variant.Results: Lambda variant had the highest risk of death (HR 1.92, 95% CI 1.37-2.68), whereas the Delta variant had the lowest risk (HR 0.50, 95% CI 0.31-0.82). Mu variant had the highest risk of hospitalization (HR: 2.39, 95% CI 1.56-3.67), Omicron the lowest (HR 0.45, 95%CI 0.23-0.90), and Gamma had the highest ICU admission rate (HR 1.95, 95%CI 1.40-2.71).Conclusion: SARS-CoV-2 variants showed distinctive risks of clinical outcomes, which could have implications for the management of infected persons during the pandemic.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:144 / 149
页数:6
相关论文
共 28 条
[1]   Altitude does not protect against SARS-CoV-2 infections and mortality due to COVID-19 [J].
Cardenas, Laura ;
Valverde-Bruffau, Valeria ;
Gonzales, Gustavo F. .
PHYSIOLOGICAL REPORTS, 2021, 9 (11)
[2]   Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada [J].
Fisman, David N. ;
Tuite, Ashleigh R. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (42) :E1619-E1625
[3]   Assessment of SARS-CoV-2 Mu Variant Emergence and Spread in Colombia [J].
Hernandez-Ortiz, Juan ;
Cardona, Andres ;
Ciuoderis, Karl ;
Averhoff, Francisco ;
Maya, Maria-Angelica ;
Cloherty, Gavin ;
Osorio, Jorge E. .
JAMA NETWORK OPEN, 2022, 5 (03)
[4]  
Iuliano AD, 2022, MMWR-MORBID MORTAL W, V71, P146, DOI [10.1101/2021.12.30.21268560v2, 10.15585/mmwr.mm7104e4]
[5]   The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance [J].
Kimura, Izumi ;
Kosugi, Yusuke ;
Wu, Jiaqi ;
Zahradnik, Jiri ;
Yamasoba, Daichi ;
Butlertanaka, Erika P. ;
Tanaka, Yuri L. ;
Uriu, Keiya ;
Liu, Yafei ;
Morizako, Nanami ;
Shirakawa, Kotaro ;
Kazuma, Yasuhiro ;
Nomura, Ryosuke ;
Horisawa, Yoshihito ;
Tokunaga, Kenzo ;
Ueno, Takamasa ;
Takaori-Kondo, Akifumi ;
Schreiber, Gideon ;
Arase, Hisashi ;
Motozono, Chihiro ;
Saito, Akatsuki ;
Nakagawa, So ;
Sato, Kei .
CELL REPORTS, 2022, 38 (02)
[6]   Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients [J].
Leon-Abarca, Juan Alonso ;
Portmann-Baracco, Arianna ;
Bryce-Alberti, Mayte ;
Ruiz-Sanchez, Carlos ;
Accinelli, Roberto Alfonso ;
Soliz, Jorge ;
Gonzales, Gustavo Francisco .
PLOS ONE, 2021, 16 (08)
[7]   The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern [J].
Lin, Lixin ;
Liu, Ying ;
Tang, Xiujuan ;
He, Daihai .
FRONTIERS IN PUBLIC HEALTH, 2021, 9
[8]  
Mandich V., 2021, GLOB J INFECT DIS CL, V7, DOI [10.17352/2455-5363.000048, DOI 10.17352/2455-5363.000048]
[9]   Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19 [J].
Moghaddar, Mehrnoosh ;
Radman, Ramtin ;
Macreadie, Ian .
MICROORGANISMS, 2021, 9 (10)
[10]   Clinical Management of COVID-19 Patients - An Update [J].
Molhave, Martin ;
Agergaard, Jane ;
Wejse, Christian .
SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (01) :4-10